what is glp-1 drug Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity New Guidelines on GLP-1 Drugs
Description
Materials and methods This study was designed following the framework delineated by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17] with rigorous attention given to registering the study protocol in the International Prospective Register for Systematic Reviews (PROSPERO) (registration code: CRD42023466256)
NA, not applicable
As shown in Table 2, the HFD-induced increases in body weight, liver index, fasting serum levels of glucose, ALT and AST were all significantly reduced by treatment with NaB
GLP-1R agonists in obesity management GLP-1R agonists, such as semaglutide, liraglutide, and tirzepatide, have gained prominence in the treatment of obesity
It also found modest reductions in BMI and waist circumference, but no significant reduction in waist-to-hip ratio
Most commercial insurance plans cover GLP-1s for diabetes management, but fewer cover them for weight management
